11 research outputs found

    Optical emission spectroscopy of electron-cyclotron-resonance-heated helium mirror plasmas

    Full text link
    In this experiment emission spectroscopy in the 3000–5000 Å range has been utilized to determine the electron temperature (15–60 eV) and ion density (2–5 x 10 11 cm −3 ) of helium plasmas produced by the Michigan mirror machine (1) (MIMI). The plasma is generated and heated by whistler-mode electron-cyclotron resonance (ECR) waves at 7.43 GHz with 400–900 W power in 80-ms-long pulses. Gas fueling is provided at the midplane region by a leak valve with a range in pressure of 3 x 10 to 2 x 10 4 Torr. Emission line intensities are interpreted using a model of the important collisional and radiative processes occurring in the plasma. The model examines secondary processes such as radiation trapping, excitation transfer between levels of the carne principle quantum number, and excitation front metastable states for plasmas in the parameter range of MIMI ( n c = 1−6 x 10 11 cm −3 ). Front the analysis of line intensity ratios for neutral helium, the electron temperature is measured and its dependence upon the gas pressure and microwave power is determined. These temperatures agree with those obtained by Langmuir probe measurements. Art analysis of the line intensity ratio between singly ionized helium and neutral helium yields a measurement of the ion density which is in good agreement with electron density measurements made by a microwave interferometer.Peer Reviewedhttp://deepblue.lib.umich.edu/bitstream/2027.42/45473/1/11090_2005_Article_BF01447032.pd

    Cause of Death and Predictors of All-Cause Mortality in Anticoagulated Patients With Nonvalvular Atrial Fibrillation : Data From ROCKET AF

    Get PDF
    M. Kaste on työryhmän ROCKET AF Steering Comm jäsen.Background-Atrial fibrillation is associated with higher mortality. Identification of causes of death and contemporary risk factors for all-cause mortality may guide interventions. Methods and Results-In the Rivaroxaban Once Daily Oral Direct Factor Xa Inhibition Compared with Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation (ROCKET AF) study, patients with nonvalvular atrial fibrillation were randomized to rivaroxaban or dose-adjusted warfarin. Cox proportional hazards regression with backward elimination identified factors at randomization that were independently associated with all-cause mortality in the 14 171 participants in the intention-to-treat population. The median age was 73 years, and the mean CHADS(2) score was 3.5. Over 1.9 years of median follow-up, 1214 (8.6%) patients died. Kaplan-Meier mortality rates were 4.2% at 1 year and 8.9% at 2 years. The majority of classified deaths (1081) were cardiovascular (72%), whereas only 6% were nonhemorrhagic stroke or systemic embolism. No significant difference in all-cause mortality was observed between the rivaroxaban and warfarin arms (P=0.15). Heart failure (hazard ratio 1.51, 95% CI 1.33-1.70, P= 75 years (hazard ratio 1.69, 95% CI 1.51-1.90, P Conclusions-In a large population of patients anticoagulated for nonvalvular atrial fibrillation, approximate to 7 in 10 deaths were cardiovascular, whereasPeer reviewe

    Use of anticoagulants and antiplatelet agents in stable outpatients with coronary artery disease and atrial fibrillation. International CLARIFY registry

    Get PDF

    Glaciation of Orkney

    No full text

    Physiology of the antral pump and gastric emptying

    No full text
    Christopher K. Rayner, Geoffrey S. Hebbard and Michael Horowit

    Cause of death and predictors of all-cause mortality in anticoagulated patients with nonvalvular atrial fibrillation: Data from ROCKET AF

    No full text
    Background-Atrial fibrillation is associated with higher mortality. Identification of causes of death and contemporary risk factors for all-cause mortality may guide interventions. Methods and Results-In the Rivaroxaban Once Daily Oral Direct Factor Xa Inhibition Compared with Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation (ROCKET AF) study, patients with nonvalvular atrial fibrillation were randomized to rivaroxaban or dose-adjusted warfarin. Cox proportional hazards regression with backward elimination identified factors at randomization that were independently associated with all-cause mortality in the 14 171 participants in the intentionto- treat population. The median age was 73 years, and the mean CHADS2 score was 3.5. Over 1.9 years of median follow-up, 1214 (8.6%) patients died. Kaplan-Meier mortality rates were 4.2% at 1 year and 8.9% at 2 years. The majority of classified deaths (1081) were cardiovascular (72%), whereas only 6% were nonhemorrhagic stroke or systemic embolism. No significant difference in all-cause mortality was observed between the rivaroxaban and warfarin arms (P=0.15). Heart failure (hazard ratio 1.51, 95% CI 1.33-1.70, P<0.0001) and age 6575 years (hazard ratio 1.69, 95% CI 1.51-1.90, P<0.0001) were associated with higher all-cause mortality. Multiple additional characteristics were independently associated with higher mortality, with decreasing creatinine clearance, chronic obstructive pulmonary disease, male sex, peripheral vascular disease, and diabetes being among the most strongly associated (model C-index 0.677). Conclusions-In a large population of patients anticoagulated for nonvalvular atrial fibrillation, 487 in 10 deaths were cardiovascular, whereas <1 in 10 deaths were caused by nonhemorrhagic stroke or systemic embolism. Optimal prevention and treatment of heart failure, renal impairment, chronic obstructive pulmonary disease, and diabetes may improve survival
    corecore